Meeting
2024 ASCO Annual Meeting
A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.
Authors
Lucia Masarova
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Lucia Masarova , Meixian Huang , Swati Goel , Sharon Bledsoe , Naveen Pemmaraju , Tapan M. Kadia , Prithviraj Bose , Jo Ishizawa , Guillermo Montalban Bravo , Mi-Ae Lyu , Tara Sadeghi , Ekaterina Assatiani , Simrit Parmar , Christopher Flowers , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT05423691
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6580)
DOI
10.1200/JCO.2024.42.16_suppl.6580
Abstract #
6580
Poster Bd #
139
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
First Author: Francesco Passamonti
Poster
2022 ASCO Annual Meeting
A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis.
First Author: Haris Ali
Poster
2022 ASCO Annual Meeting
Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).
First Author: Naveen Pemmaraju
Poster
2023 ASCO Annual Meeting
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.
First Author: Yi Zhang